#METABOLOMICS WORKBENCH michaelsa93_20170809_131512_mwtab.txt DATATRACK_ID:1195 STUDY_ID:ST000844 ANALYSIS_ID:AN001366
VERSION             	1
CREATED_ON             	August 10, 2017, 2:47 pm
#PROJECT
PR:PROJECT_TITLE                 	Statin Immuno-Metabolomics in Asthma
PR:PROJECT_TYPE                  	Placebo-controled trial
PR:PROJECT_SUMMARY               	Innovative and novel therapies are urgently needed for the treatment of patients
PR:PROJECT_SUMMARY               	with severe asthma, especially those who are refractory to standard-of-care
PR:PROJECT_SUMMARY               	bronchodilators and inhaled corticosteroids. The Zeki lab is investigating the
PR:PROJECT_SUMMARY               	role of the mevalonate (MA) pathway, in the pathogenesis of airway inflammation
PR:PROJECT_SUMMARY               	and remodeling. Although statins all inhibit HMGCR in the same manner in terms
PR:PROJECT_SUMMARY               	of enzyme binding site, the statins’ varied physiochemical properties with
PR:PROJECT_SUMMARY               	respect to their polarity (i.e. lipophilicity) result in very different immune
PR:PROJECT_SUMMARY               	and lipid effects. The major significance of this work is to advance a new class
PR:PROJECT_SUMMARY               	of inhaler therapies for asthma; the statins which work by an entirely different
PR:PROJECT_SUMMARY               	mechanism than current ICS/LABA mainstays. Evidence suggests that statins may
PR:PROJECT_SUMMARY               	have an additive benefit to corticosteroids in asthma, thereby confirming a
PR:PROJECT_SUMMARY               	unique mechanism, namely via MVA pathway inhibition. This becomes particularly
PR:PROJECT_SUMMARY               	important in the severe asthma population which is highly
PR:PROJECT_SUMMARY               	corticosteroid-resistant, is poorly controlled with high exacerbation rates and
PR:PROJECT_SUMMARY               	hospitalizations, and has the highest healthcare costs of all asthma phenotypes.
PR:PROJECT_SUMMARY               	In essence, the potential public health impact of even an incremental
PR:PROJECT_SUMMARY               	improvement in asthma symptom control cannot be underestimated. Even the
PR:PROJECT_SUMMARY               	prevention of 1 asthma attack preserves lung function and reduces the adverse
PR:PROJECT_SUMMARY               	personal and financial impact. This study aimed to determine if statin polarity
PR:PROJECT_SUMMARY               	affects airway drug concentration and systemic drug absorption and to determine
PR:PROJECT_SUMMARY               	the effect of inhaled statins on naïve airway immune cell populations and
PR:PROJECT_SUMMARY               	alveolar-capillary membrane and epithelial barrier integrity in healthy rhesus
PR:PROJECT_SUMMARY               	monkeys. In this particular component of the study, we investigated the
PR:PROJECT_SUMMARY               	metabolic effects resulting from the use of statins in these healthy rhesus
PR:PROJECT_SUMMARY               	monkeys. Specifically, the Newman lab analyzed for lipid mediator (oxylipin,
PR:PROJECT_SUMMARY               	endocannabinoid, fatty acid, and nitro lipid) in lung and trachea tissue,
PR:PROJECT_SUMMARY               	plasma, and BAL and bile acid changes in the lung and trachea tissue and plasma.
PR:INSTITUTE                     	University of California, Davis
PR:DEPARTMENT                    	Internal Medicine
PR:LAST_NAME                     	Zeki
PR:FIRST_NAME                    	Amir
PR:ADDRESS                       	2825 J St. Suite 400 Sacramento, CA 95816
PR:EMAIL                         	aazeki@ucdavis.edu
PR:PHONE                         	(916) 734-8230
#STUDY
ST:STUDY_TITLE                   	Statin Immuno-Metabolomics in Asthma (part II)
ST:STUDY_TYPE                    	Placebo-controled trial
ST:STUDY_SUMMARY                 	Innovative and novel therapies are urgently needed for the treatment of patients
ST:STUDY_SUMMARY                 	with severe asthma, especially those who are refractory to standard-of-care
ST:STUDY_SUMMARY                 	bronchodilators and inhaled corticosteroids. The Zeki lab is investigating the
ST:STUDY_SUMMARY                 	role of the mevalonate (MA) pathway, in the pathogenesis of airway inflammation
ST:STUDY_SUMMARY                 	and remodeling. Although statins all inhibit HMGCR in the same manner in terms
ST:STUDY_SUMMARY                 	of enzyme binding site, the statins’ varied physiochemical properties with
ST:STUDY_SUMMARY                 	respect to their polarity (i.e. lipophilicity) result in very different immune
ST:STUDY_SUMMARY                 	and lipid effects. The major significance of this work is to advance a new class
ST:STUDY_SUMMARY                 	of inhaler therapies for asthma; the statins which work by an entirely different
ST:STUDY_SUMMARY                 	mechanism than current ICS/LABA mainstays. Evidence suggests that statins may
ST:STUDY_SUMMARY                 	have an additive benefit to corticosteroids in asthma, thereby confirming a
ST:STUDY_SUMMARY                 	unique mechanism, namely via MVA pathway inhibition. This becomes particularly
ST:STUDY_SUMMARY                 	important in the severe asthma population which is highly
ST:STUDY_SUMMARY                 	corticosteroid-resistant, is poorly controlled with high exacerbation rates and
ST:STUDY_SUMMARY                 	hospitalizations, and has the highest healthcare costs of all asthma phenotypes.
ST:STUDY_SUMMARY                 	In essence, the potential public health impact of even an incremental
ST:STUDY_SUMMARY                 	improvement in asthma symptom control cannot be underestimated. Even the
ST:STUDY_SUMMARY                 	prevention of 1 asthma attack preserves lung function and reduces the adverse
ST:STUDY_SUMMARY                 	personal and financial impact. This study aimed to determine if statin polarity
ST:STUDY_SUMMARY                 	affects airway drug concentration and systemic drug absorption and to determine
ST:STUDY_SUMMARY                 	the effect of inhaled statins on naïve airway immune cell populations and
ST:STUDY_SUMMARY                 	alveolar-capillary membrane and epithelial barrier integrity in healthy rhesus
ST:STUDY_SUMMARY                 	monkeys. In this particular component of the study, we investigated the
ST:STUDY_SUMMARY                 	metabolic effects resulting from the use of statins in these healthy rhesus
ST:STUDY_SUMMARY                 	monkeys. Specifically, the Newman lab analyzed for lipid mediator (oxylipin,
ST:STUDY_SUMMARY                 	endocannabinoid, fatty acid, and nitro lipid) in lung and trachea tissue,
ST:STUDY_SUMMARY                 	plasma, and BAL and bile acid changes in the lung and trachea tissue and plasma.
ST:INSTITUTE                     	USDA
ST:DEPARTMENT                    	Obesity and metabolism research unit
ST:LABORATORY                    	Newman's Lab
ST:LAST_NAME                     	Newman
ST:FIRST_NAME                    	John
ST:ADDRESS                       	430 West Health Sciences Dr. Davis, Ca, 95616
ST:EMAIL                         	John.Newman@ars.usda.gov
ST:PHONE                         	(530) 752-1009
#SUBJECT
SU:SUBJECT_TYPE                  	Animal
SU:SUBJECT_SPECIES               	Rhesus Macaque
SU:TAXONOMY_ID                   	9544
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-14	Treatment:Control | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-32	Treatment:Control | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-23	Treatment:Control | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-09	Treatment:Simvastatin | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-19	Treatment:Simvastatin | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-26	Treatment:Simvastatin | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-04	Treatment:Control | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-34	Treatment:Control | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-08	Treatment:Control | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-25	Treatment:Simvastatin | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-13	Treatment:Simvastatin | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-06 Rep Avg.	Treatment:Simvastatin | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-29	Treatment:Control | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-11	Treatment:Control | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-05	Treatment:Control | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-10	Treatment:Simvastatin | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-21	Treatment:Simvastatin | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-35	Treatment:Simvastatin | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-33	Treatment:Control | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-31	Treatment:Control | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-20	Treatment:Control | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-24	Treatment:Pravastatin | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-36	Treatment:Pravastatin | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-22	Treatment:Pravastatin | Day:Day 0	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-18	Treatment:Control | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-15	Treatment:Control | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-17	Treatment:Control | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-27	Treatment:Pravastatin | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-02	Treatment:Pravastatin | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-07 Rep Avg.	Treatment:Pravastatin | Day:Day 8	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-12	Treatment:Control | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-01	Treatment:Control | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-30	Treatment:Control | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-28	Treatment:Pravastatin | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-16	Treatment:Pravastatin | Day:Day 12	
SUBJECT_SAMPLE_FACTORS           	-	PLAZ-03	Treatment:Pravastatin | Day:Day 12	
#COLLECTION
CO:COLLECTION_SUMMARY            	Monkeys were treated with placebo or Provastatin for 12 days. Further, after the
CO:COLLECTION_SUMMARY            	wash out period animals were treated with Simvastatin for 12 days. Lung wash
CO:COLLECTION_SUMMARY            	fluid was collected at day 0, 8 and 12 of each treatment.
CO:SAMPLE_TYPE                   	Blood
CO:BLOOD_SERUM_OR_PLASMA         	Plasma
#TREATMENT
TR:TREATMENT_SUMMARY             	Monkeys were treated (by inhalation) with placebo or Provastatin for 12 days.
TR:TREATMENT_SUMMARY             	Further, after the wash out period animals were treated with Simvastatin for 12
TR:TREATMENT_SUMMARY             	days. Lung wash fluid was collected at day 0, 8 and 12 of each treatment.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Oxylipins, endocannabinoids, bile acids and fatty acids were isolated from an
SP:SAMPLEPREP_SUMMARY            	aliquot of 20μl plasma in Eppendorf tubes. The tube was spiked was 5ul of
SP:SAMPLEPREP_SUMMARY            	OxyEndo Fusion, 10μl spike of Bile Acid SSTD Solutions, and 5μl of BHT/EDTA
SP:SAMPLEPREP_SUMMARY            	solution. A total of 100μl CUDA/PHAU in methanol was added to the tube, before
SP:SAMPLEPREP_SUMMARY            	it was capped, vortexed, and centrifuged (3 min, 10,000 RCF, room temp). It was
SP:SAMPLEPREP_SUMMARY            	then placed on wet ice for 5 min. Next it was spin filtered with Millapore spin
SP:SAMPLEPREP_SUMMARY            	filters (0.1 µm, Millipore, Billerica, MA) at 8 ºC, 4500 RPM for 3 min, before
SP:SAMPLEPREP_SUMMARY            	being transferred to 2 mL LC-MS amber vials. Extracts were stored at -20ºC
SP:SAMPLEPREP_SUMMARY            	until analysis by UPLC-MS/MS. The internal standard was used to quantify the
SP:SAMPLEPREP_SUMMARY            	recovery of surrogate standards.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE        	Reversed phase
CH:INSTRUMENT_NAME            	Waters Acquity UPLC
CH:COLUMN_NAME                	Acquity UPLC BEH C18 1.7μm 2.1 × 100 mm column
CH:FLOW_GRADIENT              	See protocol/methods file
CH:FLOW_RATE                  	0.25 mL/min
CH:COLUMN_TEMPERATURE         	60 °C
CH:SOLVENT_A                  	0.1% acetic acid
CH:SOLVENT_B                  	90% ACN / 10% IPA
CH:INTERNAL_STANDARD          	See protocol/methods file
CH:RETENTION_TIME             	See protocol/methods file
CH:SAMPLE_INJECTION           	5 µL
CH:ANALYTICAL_TIME            	20 min
CH:WEAK_WASH_SOLVENT_NAME     	20% methanol, 10% isopropanol
CH:WEAK_WASH_VOLUME           	600 µL
CH:STRONG_WASH_SOLVENT_NAME   	50:50 Acetonitrile:Methanol
CH:STRONG_WASH_VOLUME         	600 µL
#ANALYSIS
AN:ANALYSIS_TYPE            	MS
#MS
MS:INSTRUMENT_NAME          	Waters Acquity UPLC
MS:INSTRUMENT_TYPE          	API 6500 QTrap
MS:MS_TYPE                  	ESI
MS:ION_MODE                 	NEGATIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	Concentration (nM)
MS_METABOLITE_DATA_START
Samples	PLAZ-14	PLAZ-32	PLAZ-23	PLAZ-09	PLAZ-19	PLAZ-26	PLAZ-04	PLAZ-34	PLAZ-08	PLAZ-25	PLAZ-13	PLAZ-06 Rep Avg.	PLAZ-29	PLAZ-11	PLAZ-05	PLAZ-10	PLAZ-21	PLAZ-35	PLAZ-33	PLAZ-31	PLAZ-20	PLAZ-24	PLAZ-36	PLAZ-22	PLAZ-18	PLAZ-15	PLAZ-17	PLAZ-27	PLAZ-02	PLAZ-07 Rep Avg.	PLAZ-12	PLAZ-01	PLAZ-30	PLAZ-28	PLAZ-16	PLAZ-03
Factors	Treatment:Control | Day:Day 0	Treatment:Control | Day:Day 0	Treatment:Control | Day:Day 0	Treatment:Simvastatin | Day:Day 0	Treatment:Simvastatin | Day:Day 0	Treatment:Simvastatin | Day:Day 0	Treatment:Control | Day:Day 8	Treatment:Control | Day:Day 8	Treatment:Control | Day:Day 8	Treatment:Simvastatin | Day:Day 8	Treatment:Simvastatin | Day:Day 8	Treatment:Simvastatin | Day:Day 8	Treatment:Control | Day:Day 12	Treatment:Control | Day:Day 12	Treatment:Control | Day:Day 12	Treatment:Simvastatin | Day:Day 12	Treatment:Simvastatin | Day:Day 12	Treatment:Simvastatin | Day:Day 12	Treatment:Control | Day:Day 0	Treatment:Control | Day:Day 0	Treatment:Control | Day:Day 0	Treatment:Pravastatin | Day:Day 0	Treatment:Pravastatin | Day:Day 0	Treatment:Pravastatin | Day:Day 0	Treatment:Control | Day:Day 8	Treatment:Control | Day:Day 8	Treatment:Control | Day:Day 8	Treatment:Pravastatin | Day:Day 8	Treatment:Pravastatin | Day:Day 8	Treatment:Pravastatin | Day:Day 8	Treatment:Control | Day:Day 12	Treatment:Control | Day:Day 12	Treatment:Control | Day:Day 12	Treatment:Pravastatin | Day:Day 12	Treatment:Pravastatin | Day:Day 12	Treatment:Pravastatin | Day:Day 12
6-keto PGF1a	0.04	0.06	0.13	0.04	0.08	0.1	0.12	0.06	\N	0.03	\N	0.04	0.11	0.15	0.04	\N	0.04	0	0.05	\N	0.11	0.09	0.04	0.17	0.12	\N	0.12	0.13	0.03	0.03	0.03	0.07	0.06	0.07	0.05	0.05
TXB2	5.36	14.2	31.5	26.4	21.7	9.39	4.42	2.56	8.99	\N	8.89	0.08	6.01	7.73	26.6	10.3	10.8	4.66	7.21	19.3	22.1	16.1	15.5	12.1	25.9	4.84	48.4	13.6	5.6	6.59	2.24	\N	6.86	3.82	2.71	\N
PGE2	1.02	1.04	1.33	0.84	0.28	0.51	0.15	0.14	0.45	\N	0.14	0.1	0.39	0.83	0.64	0.27	0.24	0.23	0.12	0.63	0.86	0.33	0.73	0.34	0.86	0.13	0.69	0.29	0.22	0.07	0.2	\N	0.19	0.27	0.11	0.01
PGD2	0.24	0.39	0.47	0.51	0.73	0.48	0.41	0.34	0.16	0.24	0.16	0.22	0.25	1.13	0.53	0.08	0.18	0.33	0.38	0.51	0.91	0.94	0.51	0.88	0.54	0.22	0.42	0.42	0.36	0.1	0.15	0.52	0.49	0.21	0.56	0.37
15-deoxy PGJ2	0.43	\N	\N	0.37	0.25	0.44	0.44	0.08	0.38	0.41	0.65	0.3	0.2	0.92	0.48	0.36	0.34	0.01	\N	\N	0	0.28	0.14	\N	0.19	0.55	0.15	0.32	0.36	0.37	0.48	0.68	0.47	0.24	0.27	0.44
PGF2a	0.64	1.09	3.01	0.79	0.72	1.47	0.34	1.2	0.47	0.26	0.72	0.45	0.6	0.9	1.74	0.54	0.45	0.01	0.67	1.25	1.94	0.81	0.88	1.23	0.62	0.36	1.33	0.42	0.49	0.36	0.62	0.5	0.7	0.2	0.55	0.31
11-HETE	1.56	1.76	2.42	2.25	1.86	0.89	0.62	0.24	1.03	0.11	1.01	0.33	0.64	1.26	2.38	0.86	0.95	0.51	1.05	1.97	2.15	1.35	1.8	1.03	1.53	0.55	1.56	1.33	0.67	0.4	0.6	0.3	0.62	0.47	0.51	0.29
6-trans-LTB4	0.08	0.07	\N	\N	\N	0.06	\N	\N	\N	\N	\N	0	1.25	0.8	\N	\N	\N	\N	\N	\N	0.33	\N	0.77	3.44	3.78	0.37	0.27	\N	0.17	0.19	0.39	\N	\N	\N	\N	\N
SUM-TriHOME	17.7	8.72	6.94	5.33	10.7	7.57	4.93	6.37	4.76	2.02	6.24	6.58	25.1	18.2	18	6.75	5.12	5.57	6.14	4.7	10.7	6.43	14.2	21.1	37.5	9.06	11	3.26	8.58	6.15	12.1	6.61	4.1	4.04	3.64	4.76
9_10-e-DiHO	7.08	2.94	2.03	3.07	2.37	3.9	2.2	1.56	1.43	0.64	2.46	5.16	6.25	6.2	1.77	3.59	2.21	1.78	2.57	3.14	1.32	5.32	3.17	4.86	2.77	2.46	3.08	4.54	3.14	1.07	8.03	5.84	1.9	1.65	3.86	2.21
12_13-DiHOME	9.08	12.3	7.15	17.2	10.3	9.8	5.07	4.34	2.69	6.98	12.3	8.54	6.13	12.4	7.5	17.8	6.1	8.05	9.87	13.8	7.01	19.3	17.8	9.37	4.77	4.88	2.71	19.6	7.68	4.08	6.55	4.78	4.91	5.65	8.07	4.94
9_10-DiHOME	22.9	21.2	8.86	26.2	19.5	19	15	8.07	7.19	31.6	38.2	17.2	13.5	15.8	14.6	35.4	9.53	14.8	24.4	33	9.68	32.1	20.2	18	15.1	6.48	4.41	78.4	21.4	12.7	17.9	8.74	13.1	12.3	17.1	12.1
15_16-DiHODE	16.6	44.3	10.1	41.1	50.4	34.3	8.75	18.6	6.61	11.4	22.1	25.55	13.1	32.6	12.1	35.8	15	23.3	23.1	50.7	19.2	30.7	30.8	16.7	7.76	16.8	7.71	23.5	14.4	7.44	14.4	18	13.1	9.69	20.4	11.8
9_10-DiHODE	1.18	1.31	0.41	1.71	1.38	1.11	0.32	0.46	0.15	0.62	0.95	0.81	0.55	0.89	0.34	1.46	0.53	0.96	1.23	1.5	0.55	1.47	1.26	0.95	0.23	0.5	0.18	1.34	0.48	0.28	0.63	0.47	0.4	0.32	0.76	0.5
14_15-DiHETrE	1.11	0.94	1.57	1.72	0.91	0.94	0.75	0.35	1.14	0.52	1.24	0.83	0.75	0.99	1.19	1.64	0.77	0.79	1.28	0.91	1.27	1.91	0.65	1.41	0.67	0.8	0.98	1.29	0.81	0.75	0.96	0.97	1.3	1.19	0.98	0.94
11_12-DiHETrE	1.3	0.66	1.23	1.86	0.96	0.82	0.67	0.26	0.99	0.41	1.19	0.79	0.69	0.8	1.15	1.63	0.77	0.72	1.16	0.63	1.21	2.12	0.29	1.35	0.54	0.46	0.6	1.28	0.77	0.54	0.88	0.61	0.82	0.95	0.87	0.95
8_9-DiHETrE	0.82	0.56	0.65	0.7	0.56	0.33	0.54	0.22	0.6	0.29	0.7	0.53	0.46	1.24	0.75	0.9	0.64	0.57	0.53	0.5	1.09	1.71	0.33	1.08	0.58	0.39	0.3	0.75	0.71	0.3	0.81	0.58	0.91	0.56	0.73	0.48
19_20-DiHDoPA	7.42	4.66	9.95	11.2	5.84	5.94	4.83	2.2	6.81	2.66	10	5.69	4.52	5.8	8.94	9.21	8.08	4.77	8.49	4.83	8.94	14.9	4.39	7.89	4.4	4.8	6.48	9.98	7.27	5.83	5.68	4.78	8.97	6.79	8.31	4.91
13-HODE	420	225	143	242	299	203	60.9	60.7	26.8	68.1	140	56.9	256	132	109	119	46.9	68.5	156	87.5	79.8	135	178	478	580	59.3	51.2	162	135	74.65	397	33.5	41.6	40.3	69.3	41
9-HODE	57.6	31.6	22.7	54.6	29.6	29.3	20.6	10.3	7.27	20	40.1	25.3	23	21	18.1	36.4	23.1	22.5	36.9	25.4	15.1	42.4	36.9	33.6	36.7	9.39	8.3	47	34.6	16.6	26.5	11.5	12.3	12.5	23	18.6
13-HOTE	26	12.4	5.55	9.75	22.7	11.6	1.3	5.08	0.52	1.62	3.92	2.41	24.2	13.7	5	4.12	2.3	3.36	10.6	4.75	4.95	6.91	13	30.4	35.4	5.93	2.46	4.05	6.43	3.61	40.6	1.41	1.03	1.36	4.7	1.05
15-HETE	3.72	2.62	3.25	1.91	2.81	3.35	0.42	1.47	0.93	0.17	1.02	0.68	5.55	4.65	3.17	1.09	1.1	1.17	2.19	1.56	4.3	1.6	2.32	7.26	12.5	1.24	2.42	1.25	1.74	1.08	7.09	0.8	0.47	0.69	1.04	0.09
12-HETE	85.4	85.5	169	97.6	178	76.3	8.87	17.8	27	1.34	57.8	2.01	81.5	84.5	95.2	23.3	21.8	10.7	35.8	74.8	103	71.4	162	130	250	24.1	103	47.6	46.2	12.75	114	2.32	19.8	11.7	16.5	1.6
8-HETE	0.65	0.39	0.52	0.71	0.53	0.32	0.18	\N	0.23	0.13	0.37	0.36	0.45	1.36	0.44	0.42	0.19	\N	0.35	0.35	0.54	0.6	0.26	0.83	0.97	0.29	0.59	0.5	0.46	0.45	0.81	0.56	0.18	0.07	0.07	0.3
5-HETE	3.9	4.25	5.08	3.23	2.59	1.57	2.11	0.93	1.25	0.59	4.47	2.39	2.94	3.13	3.16	3.72	8.98	2.68	4.75	4.61	4.88	3.59	3.52	4.97	3.15	2.89	2.09	5.04	3.26	2.17	4.96	3.37	3.1	2.51	4.78	1.76
15-HEPE	1.4	0.99	0.45	0.53	1.47	1.5	0.18	0.74	0.11	0.05	0.27	0.24	2.43	1.76	0.58	0.35	0.26	0.26	0.64	0.41	0.95	0.47	1.52	4.05	4.33	0.61	0.5	0.21	0.72	0.26	3.52	0.11	0.03	0.01	0.24	0.1
12-HEPE	7.14	15.1	12.6	12.6	13.3	7.82	0.33	1.63	0.86	0.32	1.79	0.44	4.05	5.73	3.23	1.78	0.97	1.15	3.09	3.77	4.81	6.75	6.78	11	8.55	1.75	3.84	1.95	2.29	1.04	7.95	0.62	0.82	1.13	1.46	0.55
5-HEPE	1.73	2.91	1.45	2.33	1.62	1.11	0.92	0.55	0.32	0.58	1.27	0.93	1.62	2.17	0.71	1.72	1.77	1.56	2.57	3.31	2.12	2.21	4.09	2.15	0.84	2.09	0.82	2.19	0.77	0.77	2.71	2.01	1.35	1.02	1.63	0.91
17-HDoHE	17.2	10.3	2.84	2.14	18.4	19.1	0.96	12.5	\N	\N	2.11	0.33	52.4	31	3.13	\N	\N	2.44	6.43	0.52	6.2	4.35	13.4	68.5	156	10.4	3.83	\N	5.82	5.84	64.3	0.35	\N	\N	1.53	0.23
14-HDoHE	88.3	93.8	70.5	62.7	93.5	64.1	2.57	33.3	3.59	0.47	8.8	0.44	119	72.5	28.2	4.63	4.03	7.36	27.3	13	29.1	27.3	33.8	198	386	21.7	21.8	5.98	30.6	18.9	159	1.92	3.37	6.67	10.2	0.49
4-HDoHE	1.2	1.09	1.03	0.98	0.8	1.1	0.95	0.42	0.65	0.23	0.89	1.06	1.18	1.57	0.48	1.45	1.57	1.08	1.45	2.06	0.93	1.38	2.33	3.3	1.53	2.24	1.81	1.66	0.97	1.68	2.13	1.62	1.2	1.18	1.46	1.3
9_10-EpO	2.37	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	1.35	70.9	\N	0.44	5.05	\N	\N	\N	20.9	\N	\N	3.08	\N	\N	\N	\N	\N	2.44	97	18.6	\N	\N	\N	9.03
12(13)-EpOME	21	10.1	6.18	16	10.2	11.5	13.4	6.95	3.65	7.81	18.4	11	13.5	12.3	3.7	14.4	12.3	11.5	19.7	9.71	2.95	12.4	22.4	12.9	12.6	8.48	3.75	18.7	12.5	11.1	13.8	8.23	8.68	10	14.1	9.56
9(10)-EpOME	10.5	2.73	2.06	4.98	2.87	5.56	7.08	2.94	2.88	3.89	8.03	5.87	5.52	4.08	2.78	5.45	2.95	4.52	8.6	2.91	1.97	3.51	9.3	7.41	8.71	1.99	2.49	6.88	7.88	6.57	7.59	3.47	2.17	3	4.95	5.48
12(13)-Ep-9-KODE	5.24	2.2	2.15	0.83	0.95	2	0.55	2.11	0.28	0.88	0.93	0.44	1.58	1.01	0.81	0.63	0.58	0.76	1.53	0.86	1.41	1.73	1.58	3.46	6.55	0.61	1.15	1.94	1.24	3.09	5.39	0.83	0.86	1.24	0.96	1.11
15(16)-EpODE	12.5	7.79	9.61	19.8	7.89	10.3	6	4.19	2.39	3.82	10.5	7.31	8.84	7.58	5.43	14.3	9.55	10.2	16.5	7.85	4.67	14.4	22.6	9.87	3.51	7.98	3.3	12.8	6.78	5.19	8.17	2.33	6.13	3.81	10.3	5.49
12(13)-EpODE	0.8	0.39	0.09	0.9	0.42	0.5	0.49	0.25	0.13	0.32	0.32	0.4	0.66	0.36	0.1	0.61	0.24	0.39	0.9	0.56	0.27	0.69	1.13	0.78	0.18	0.5	0.1	0.53	0.37	0.27	0.66	0.63	0.25	0.19	0.28	0.48
14(15)-EpETrE	0.42	0.39	0.85	0.22	0.15	0.11	0.28	0.19	0.03	0.31	0.49	0.68	0.75	2.89	0.42	0.46	0.25	0.36	0.54	0.16	0.77	0.55	0.22	0.46	0.78	\N	0	1.1	0.19	0.65	0.49	0.92	0.45	0.21	0.04	0.33
11(12)-EpETrE	0.28	0.04	0.16	0.15	0.07	0.06	0.09	\N	0.03	\N	\N	0.1	0.02	0.37	0.18	0.17	0.05	0.09	0.03	0.05	0.1	0.25	0.02	0.12	0.04	0.04	0.11	0.15	0.24	0.24	0.05	0.53	0.01	0.08	0.13	0.19
19(20)-EpDPE	0.71	1.06	1	1.51	0.17	0.2	0.47	\N	\N	0.12	0.27	0.41	\N	1.06	0.43	0.41	0.15	0.1	1.61	0.4	0.25	1.61	0.21	2.22	0.49	0	0.17	0.57	0.07	0.53	0.24	0.07	0.13	0.36	0.6	0.33
9-KODE	9.65	4.86	2.84	3.45	4.98	3.64	4.1	4.4	3.07	4.05	2.85	3.81	7.67	2.14	2.17	2.12	3.91	1.27	7.03	4.93	1.95	1.18	12.1	7.68	16.7	5.12	2.62	5.03	6.4	5.17	8.07	4.34	3.74	1.56	2.06	1.72
5-KETE	\N	0	0.25	0.14	0.03	\N	0.14	0.02	0.04	0.01	0.64	0.12	0.1	0.23	0.25	0.1	0.99	0.2	0.07	0.15	0.11	0.12	0.19	0.15	0.29	0.06	0.14	0.11	0.42	0.36	0.32	0.3	0.02	0.1	0.05	0.16
15-Keto PGE2	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
Lipoxin A4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
LTB4	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
LTB5	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5_15-DiHETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
8_15-DiHETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
Resolvin D1	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12_13-DiHODE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5_6-DiHETrE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17_18-DiHETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14_15-DiHETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
9-HOTE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20-HETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
9-HETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
9-HEPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
9(10)-EpODE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
8(9)-EpETrE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17(18)-EpETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14(15)-EpETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
11(12)-EpETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16(17)-EpDPE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13-KODE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15-KETE	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
6-keto PGF1a
TXB2
PGE2
PGD2
15-deoxy PGJ2
PGF2a
11-HETE
6-trans-LTB4
SUM-TriHOME
9_10-e-DiHO
12_13-DiHOME
9_10-DiHOME
15_16-DiHODE
9_10-DiHODE
14_15-DiHETrE
11_12-DiHETrE
8_9-DiHETrE
19_20-DiHDoPA
13-HODE
9-HODE
13-HOTE
15-HETE
12-HETE
8-HETE
5-HETE
15-HEPE
12-HEPE
5-HEPE
17-HDoHE
14-HDoHE
4-HDoHE
9_10-EpO
12(13)-EpOME
9(10)-EpOME
12(13)-Ep-9-KODE
15(16)-EpODE
12(13)-EpODE
14(15)-EpETrE
11(12)-EpETrE
19(20)-EpDPE
9-KODE
5-KETE
15-Keto PGE2
Lipoxin A4
LTB4
LTB5
5_15-DiHETE
8_15-DiHETE
Resolvin D1
12_13-DiHODE
5_6-DiHETrE
17_18-DiHETE
14_15-DiHETE
9-HOTE
20-HETE
9-HETE
9-HEPE
9(10)-EpODE
8(9)-EpETrE
17(18)-EpETE
14(15)-EpETE
11(12)-EpETE
16(17)-EpDPE
13-KODE
15-KETE
METABOLITES_END
#END
